insights_auto
Prečo akcie FARN klesli 3,92%?
Preskúmať podrobnejšiechevron_right
FARN:LON
Faron Pharmaceuticals Oy
35,07 GBX
arrow_downward
-3,92%(-1,43) 1 d.
14. 10., 9:08:58 GMT+1 · GBX
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre FARN…
Otvoriť
36,70 GBX
Vysoká
38,00 GBX
Nízka
35,07 GBX
Trh. kap.
71,19 mil.
Priem. obj.
41,22 tis.
Objem
10,38 tis.
Max. za 52 týž.
193,58 GBX
Min. za 52 týž.
34,00 GBX
Výnosy na akciu
-0,10 GBX
Akcie v obehu
31,03 mil.
Počet zamestnancov
36
Otvoriť
36,70 GBX
Vysoká
38,00 GBX
Nízka
35,07 GBX
Trh. kap.
71,19 mil.
Priem. obj.
41,22 tis.
Objem
10,38 tis.
Max. za 52 týž.
193,58 GBX
Min. za 52 týž.
34,00 GBX
Výnosy na akciu
-0,10 GBX
Akcie v obehu
31,03 mil.
Počet zamestnancov
36
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Local 3 News
·
pred 1 hodinou
RAW: NYSE: OPENING BELL (WEDNESDAY)
Seeking Alpha
·
pred 56 minútami
Stocks typically weaken ahead of midterms, then rebound, but resilience has persisted – analyst
Central Oregon Daily
·
pred 24 minútami
Wall St slides as hot CPI data fuels rate-hike bets; chips, banks weigh
Yahoo Finance
·
pred 58 minútami
This ETF Has Crushed the S&P 500 in 2026. Here's Why I Think It Still Has Room to Grow.
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Informácie o subjekte Faron Pharmaceuticals Oy